The FDA approval of Hepcludex introduces three critical considerations for clinical practice. First, this represents the inaugural FDA-approved therapy specifically targeting chronic hepatitis delta virus infection, ending a prolonged period without disease-modifying treatment options. Second, the approval applies exclusively to adults without advanced cirrhosis or those with compensated cirrhosis, reflecting the evidence base from clinical trials and defining the appropriate patient population for treatment initiation.
Third, this approval acknowledges hepatitis delta as the most severe form of chronic viral hepatitis, with disease progression substantially more rapid than hepatitis B mono-infection. Clinicians treating patients with HDV co-infection now have a pharmacologic tool to suppress viral replication and potentially slow disease progression. Early identification and treatment of eligible patients may improve long-term outcomes and reduce complications including cirrhosis, liver failure, and hepatocellular carcinoma.
Read the full article on GMJ Newsroom.
Was this article helpful?
